- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and other serious diseasesCAMBRIDGE, Mass. (BUSINESS WIRE) Repertoire Immune Medicines, a clinical-stage biotech company.
John Cox, Repertoire s CEO (left) and Douglas Cole, M.D., Repertoire s chairman (Repertoire)
Repertoire Immune Medicines has raised $189 million to advance anti-cancer T-cell therapies through the clinic while expanding its immune response drug discovery platform.
Flagship Pioneering created Repertoire by combining two of its portfolio companies, Cogen Immune Medicines and Torque Therapeutics. The VC shop oversaw the merger to bring together the immune decoding and immuno-oncology platforms that underpinned Cogen and Torque, respectively, and put former Bioverativ CEO John Cox in charge of the combined company.
Now, Repertoire has raised a series B round to support the next stage of its development. Repertoire framed the financing primarily in the context of what it will mean for the DECODE technologies it has developed to characterize the immune synapse.
Telesat Canada Announces Proposed Secured Notes Offering
04/13/2021 | 09:15am EDT
Send by mail :
Message :
Required fields
OTTAWA, April 13, 2021 (GLOBE NEWSWIRE) Telesat Canada (“Telesat”) today announced that, together with Telesat LLC, as co-issuer, it intends to issue US$500 million of senior secured notes due 2026 (the “Senior Secured Notes”) secured by a first priority lien on the collateral that secures Telesat’s existing credit agreement and existing 4.875% senior secured notes due 2027.
Telesat intends to use the net proceeds from the proposed offering of Senior Secured Notes (the “Offering”) to fund additional investment into one or more unrestricted subsidiaries for the development of Telesat Lightspeed, Telesat’s Low Earth Orbit (LEO) satellite network, for the payment of fees and expenses related to the Offering, and if the funding needs of Telesat Lightspeed are less than currently anticipated, for general corporate purposes.
Thycotic and Centrify Merge to Become a Leading Cloud Privileged Identity Security Vendor
Combined company to deliver comprehensive cloud privileged access management solutions to meet unique demands of the market, from SMB to global enterprises
News provided by
Share this article
SANTA CLARA, Calif. and WASHINGTON, April 13, 2021 /PRNewswire/
Thycotic, a leading provider of privileged access management (PAM) solutions for more than 12,500 organizations worldwide, and
Centrify, a leading provider of modern privileged access management solutions to over half of the Fortune 100, today announced that the companies have completed their
previously-announced merger to form a leading cloud identity security vendor. The combined company has now begun integrations and will operate under the temporary name ThycoticCentrify.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.